ASPI at a glance
ASP Isotopes Inc. (ASPI, SEC CIK 1921865) filed its latest 10-K annual report on April 10, 2026, a 10-Q quarterly report on November 16, 2026, an 8-K current report on October 26, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), ASP Isotopes Inc. (ASPI) reported revenue of $23.8 million (up 475.5% from FY2024) and a net loss of $159.8 million. Diluted EPS was -$2.11.
- As of September 30, 2026, 22 institutional investment managers tracked by SignalX reported holding ASP Isotopes Inc. (ASPI) shares worth $78.4 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Ainscow Robert on November 16, 2026 of 67,500 shares at $1.57 per share.
- In the last 90 days, ASPI insiders reported 2 open-market purchases ($62K) and 9 open-market sales ($1.4M) on Form 4, a net sale of $1.4M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $23.8M
- +475.5% vs prior year
- Insiders · 90 days
- 2 buys · 9 sells
- Net −$1.4M
- 13F holders
- 22 funds
- $78.4M · +0 vs prior quarter
- Latest 8-K
- Oct 26, 2026
- Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Merger risk newly added, triggered by ENDRA’s October 2, 2026 Form S-4 registration statement
- Renergen business risks incorporated by reference through Registration Statement Exhibit 99.1
- No material changes to 2025 Form 10-K risk factors beyond merger-related disclosures
- Merger execution risk, amendments or supplements to the S-4 may add material transaction information
- Carried-forward risks remain applicable, including risks disclosed in the amended 2025 Form 10-K
Management Discussion & Analysis
- Q3 revenue $5.1M, up $3.9M YoY from $1.3M, led by radiopharmacy revenue of $4.3M
- Radiopharmacy gross margin 38% vs 19% YoY; Helium and LNG worst, negative gross margin 96%
- Specialist isotopes best segment, revenue $4.257M vs $1.271M; nuclear fuels revenue $0
- Cash $201.7M; operating cash flow use $66.4M for nine months vs $19.9M YoY
- Si-28 shipments targeted Q4 2026; Helium and LNG margins expected to improve in 2027, Phase 2 estimated above $1.0B
AI summary of the ASPI 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Virginia Gas Project achieved stable liquid helium production after Phase 1 commissioning
- First helium inventory accumulating ahead of deliveries under existing offtake agreements
Item 7.01: Regulation FD Disclosure
- Tetra4, Renergen subsidiary, completed commissioning of liquid-helium production
- Stable production milestone supports potential helium supply commercialization
Item EX-99.1: Item EX-99.1
- Binding JV framework with Necsa for HALEU production at Pelindaba, advancing ASPI’s nuclear-fuel commercialization strategy
- QLE ownership approximately 80%, with Necsa retaining approximately 20% and contributing site access, safeguards, licensing support
Item 7.01: Regulation FD Disclosure
- QLE subsidiary signed a binding framework with South Africa’s Necsa for a HALEU joint venture
- Planned Pelindaba facility covers development, financing, construction, commissioning, ownership, and operations
Item 7.01: Regulation FD Disclosure
- ENDRA filed Form S-4 on October 2, 2026, advancing the proposed merger involving ASPI’s Renergen and Noble Africa subsidiaries
- Merger remains conditional on ENDRA stockholder approval, financing completion, regulatory clearances and other closing conditions
AI summaries of ASPI 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ASPI
Don't miss the next ASPI filing
- Alerts as it files. A push when ASPI files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ASPI, by share count.
- Ask anything. An AI agent that reads every ASPI filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Ainscow Robert | Sell | Nov 16, 2026 | 67,500 | $1.57 |
| Kiessling Heather | Sell | Oct 16, 2026 | 21,830 | $2.19 |
| Ainscow Robert | Sell | Oct 14, 2026 | 22,500 | $2.11 |
| Ryan Robert John Andrew | Buy | Sep 30, 2026 | 15,000 | $2.68 |
| Ryan Robert John Andrew | Buy | Sep 28, 2026 | 8,000 | $2.70 |
| Ainscow Robert | Sell | Sep 8, 2026 | 8,438 | $4.29 |
| Mann Paul Elliot | Sell | Sep 4, 2026 | 83,759 | $4.10 |
| Mann Paul Elliot | Sell | Sep 3, 2026 | 83,758 | $3.92 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $4.1M | $23.8M |
| Gross Profit | - | $1.6M | $3.4M |
| Operating Income | - | -$26.4M | -$59.9M |
| Net Income | - | -$32.4M | -$159.8M |
| Gross Margin | - | 38.6% | 14.3% |
| Op. Margin | - | -635.9% | -251.2% |
| Net Margin | - | -782.4% | -670.2% |
| Balance Sheet | |||
| Total Assets | $27.5M | $94.3M | $498.0M |
| Equity | $16.3M | $47.9M | $204.2M |
| ROE | - | -67.7% | -78.3% |
| Per Share | |||
| EPS | - | $-0.63 | $-2.11 |
| Cash Flow | |||
| Operating CF | - | -$16.7M | -$37.8M |
| CapEx | - | $9.7M | $9.7M |
Source: XBRL data in ASP Isotopes Inc. (ASPI)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ASPI share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 22 | $78.4M |
| Q2 2026 | 22 | $143.3M |
| Q1 2026 | 21 | $95.6M |
| Q4 2025 | 21 | $135.6M |
| Q3 2025 | 22 | $188.4M |
| Q2 2025 | 22 | $85.6M |
| Q1 2025 | 18 | $29.9M |
| Q4 2024 | 14 | $25.6M |
- Citadel Advisors LLC+2.15M (+601%)
- BlackRock+1.61M (+17%)
- Vanguard Capital Management LLC+1.09M (+22%)
- Citigroup+416.0K (+343%)
- Goldman Sachs Group+337.6K (+59%)
- Morgan Stanley−180.5K (-16%)
- Invesco Ltd−139.3K (-68%)
- Wells Fargo & Co−63.0K (-54%)
- JPMorgan Chase & Co−1.6K (-1%)
- PNC Financial Services−1.3K (-87%)
- Millennium Management+485.1K
- Principal Financial Group+15.6K
- Raymond James Financial+15.3K
- Allstate−23.4K
- FMR LLC (Fidelity)−17.8K
- AQR Capital Management−13.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 162 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ASPI filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 18, 2026 | - | - | - |
| 10-Q | Nov 16, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 26, 2026 | - | Analysis | - |
| 4 | Oct 21, 2026 | - | - | - |
| 4 | Oct 16, 2026 | - | - | - |
| 8-K | Oct 15, 2026 | - | Analysis | - |
| 8-K | Oct 2, 2026 | - | Analysis | - |
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Sep 30, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 8-K | Aug 20, 2026 | - | Analysis | - |
| 8-K | Aug 20, 2026 | - | Analysis | - |
| 8-K | Aug 18, 2026 | - | Analysis | - |
| 10-Q | Aug 14, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 8-K | Jul 28, 2026 | - | Analysis | - |
| 8-K | Jul 21, 2026 | - | - | - |
| 8-K | Jul 16, 2026 | - | - | - |
Related Health Care companies
- FTK · FLOTEK INDUSTRIES INC/CN/Miscellaneous Chemical Products
- OEC · Orion S.A.Miscellaneous Chemical Products
- WDFC · WD 40 COMiscellaneous Chemical Products
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
ASPI SEC filings: frequently asked questions
Are ASPI insiders buying or selling?
In the last 90 days, ASP Isotopes Inc. (ASPI) officers, directors and 10% owners reported 2 open-market purchases worth $61,800 by 1 insider and 9 open-market sales worth $1.4 million by 4 insiders on Form 4, a net sale of $1.4 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ASPI stock?
As of September 30, 2026, the largest ASP Isotopes Inc. (ASPI) holders among the 13F filers tracked by SignalX were BlackRock ($28.7 million), Vanguard Capital Management LLC ($16.1 million), State Street Corp ($7.7 million), Citadel Advisors LLC ($6.6 million), Vanguard Portfolio Management LLC ($3.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ASPI's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), ASP Isotopes Inc. (ASPI) reported revenue of $23.8 million (up 475.5% from FY2024) and a net loss of $159.8 million. Diluted EPS was -$2.11. The figures come from the XBRL data in the 10-K.
What did ASPI report in its latest 8-K?
ASP Isotopes Inc. (ASPI) filed an 8-K on October 26, 2026 reporting Item 7.01 (Regulation FD Disclosure). Virginia Gas Project achieved stable liquid helium production after Phase 1 commissioning.
What are the latest ASPI SEC filings?
ASP Isotopes Inc. (ASPI) filed its latest 10-K annual report on April 10, 2026, a 10-Q quarterly report on November 16, 2026, an 8-K current report on October 26, 2026 and a Form 4 insider filing on November 18, 2026.
What is ASPI's SEC CIK number?
ASP Isotopes Inc. (ASPI)'s SEC Central Index Key (CIK) is 1921865. EDGAR lists every ASPI filing under that number.
Ask anything about ASPI
The research agent reads ASPI's filings, financials, insider trades and 13F holders, then answers with sources.